Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03941743 · ClinicalTrials.gov registry record · Phase 1
Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03941743: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03941743 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03941743, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This trial phase I studies how well fingolimod works in preventing chemotherapy-induced nerve pain (neuropathy) in patients with breast cancer who are taking paclitaxel. Fingolimod acts by suppressing immune reactions in the brain. This study is being done to see if fingolimod can reduce neuropathy caused by paclitaxel.
Interventions
- OTHER Questionnaire Administration
- DRUG Fingolimod
- DRUG Fingolimod Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2021-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03941743
The ClinicalTrials.gov registry entry for NCT03941743 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT03941743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03941743 about?
NCT03941743 is a clinical study titled "Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer". This trial phase I studies how well fingolimod works in preventing chemotherapy-induced nerve pain (neuropathy) in patients with breast cancer who are taking paclitaxel. Fingolimod acts by suppressing immune reactions in the brain. This study is being done to see if fingolimod can reduce neuropathy ...
What is the current status of trial NCT03941743?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-12-12. Estimated completion is 2021-11-23.
What interventions are being tested in trial NCT03941743?
The interventions under investigation include: Questionnaire Administration (OTHER), Fingolimod (DRUG), Fingolimod Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03941743?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.